PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31771617-0	2019	DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.	Sorafenib	31-40	DNA methyltransferase 3 beta	Homo sapiens	0-6	
31771617-13	2019	Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment.	Sorafenib	66-75	DNA methyltransferase 3 beta	Homo sapiens	18-24	
31771617-14	2019	Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells.	Sorafenib	92-101	DNA methyltransferase 3 beta	Homo sapiens	19-25	
31771617-14	2019	Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells.	Sorafenib	148-157	DNA methyltransferase 3 beta	Homo sapiens	19-25	
31771617-15	2019	CONCLUSIONS: The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC.	Sorafenib	111-120	DNA methyltransferase 3 beta	Homo sapiens	17-23	
31771617-17	2019	Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC.	Sorafenib	184-193	DNA methyltransferase 3 beta	Homo sapiens	60-66